GHRH Treatment Breaks the Visceral Fat-Low Growth Hormone Cycle and Cuts Cardiovascular Risk

This review synthesizes evidence that growth hormone-releasing hormone (GHRH) treatment significantly reduces visceral fat, improves dyslipidemia, and lowers cardiovascular risk markers in both HIV-infected patients and individuals with general obesity. The underlying mechanism involves a vicious cycle: excess visceral fat suppresses GH secretion (through hyperinsulinemia, elevated free fatty acids, increased somatostatin tone, and reduced ghrelin), and low GH further promotes visceral fat accumulation due to decreased lipolysis. GHRH breaks this cycle by restoring endogenous basal and pulsatile GH secretion without altering pulse frequency — a more physiological approach than direct GH injection.

Narrative review synthesizing data from clinical studies in HIV-infected populations (who commonly develop visceral lipodystrophy) and generally obese individuals. Reviews evidence on GHRH's effects on visceral fat, lipid profiles, inflammatory markers, and cardiovascular risk indices.

Visceral fat is the most metabolically dangerous type of fat, driving dyslipidemia, inflammation, and cardiovascular disease. Unlike direct GH administration (which carries side effects like insulin resistance and fluid retention), GHRH works by restoring the body's own GH production patterns. This review provides evidence that targeting the GH-visceral fat cycle with GHRH could address multiple cardiometabolic risk factors simultaneously.

While GLP-1 agonists dominate the obesity drug landscape, GHRH represents a different approach — targeting the growth hormone axis rather than appetite. The visceral fat-GH vicious cycle described in this review helps explain why visceral obesity is so self-perpetuating and difficult to reverse. GHRH therapy occupies an interesting niche: it's more physiological than direct GH injection and targets a specific metabolic pathway. The HIV lipodystrophy research has been particularly valuable for understanding how hormonal disruptions drive visceral fat accumulation even without overeating.

Narrative review, not a systematic review or meta-analysis. Most clinical data come from HIV-lipodystrophy populations, which may not generalize to all forms of obesity. Long-term efficacy and safety data for GHRH treatment are lacking. Does not address potential risks of sustained GH/IGF-1 elevation.